Skip to main content
Wolfson Institute of Preventive Medicine - Barts and The London

Multiple Sclerosis COVID-19 Antibody Study now recruiting

Published:
news image

Dr Ruth Dobson of the Wolfson’s Preventive Neurology Unit is principal investigator on a study of COVID-19 seroprevalence in people with multiple sclerosis. Now in recruitment phase, the Barts MS Covid-19 Antibody study will use self-collected fingerprick blood spots to determine how many people with MS have evidence of antibodies to COVID-19, and how different disease modifying therapies affect the generation of an immune response to the virus. The study is being conducted in collaboration with colleagues at the Blizard and BartsHealth, and initially aims to recruit 500 Barts MS patients. In light of the urgency in collecting samples, the study is being crowdfunded.

Dr Dobson said: “This study will help us understand how disease modifying therapies affect immune responses, and give us information not only about coronavirus, but also about responses to vaccines, and immunity to other diseases, among both people with MS and in the general population.”